Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from CEO Mike Doustdar, especially after losing its lead in the booming obesity market to Eli Lilly & Co. The shares plunged as much as 7.7% in early trading, despite the company pledging at its Capital Markets Day to launch more than five blockbusters and deliver more than $23 billion in new sales in the coming years. This reaction indicates that investors were seeking more robust and immediate strategies to counter the market shift.
The Danish drugmaker aimed to convince investors it could compete in an increasingly crowded field it pioneered. Novo Nordisk announced plans to launch more than five drugs with "multi-blockbuster" potential by 2030 and to generate more than 150 billion Danish kroner (approximately $23 billion) in pipeline sales by 2035. The company also projects revenue growth between 2026 and 2030 to be in line with industry peers. These long-term targets, however, did not assuage immediate investor concerns, leading to a significant stock decline.
A major concern highlighted by CEO Mike Doustdar at the London event was the impending loss of patent exclusivity for semaglutide, the active ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic. This exclusivity is set to expire starting in the early next decade, with the U.S. patent expiring in 2032, impacting more than half of the company's sales. Doustdar acknowledged this "elephant in the room," stating, "We created an incredibly attractive market, and now almost every other single pharma company, big or small, is trying to come and compete with us. We need to be ready for that."
Doustdar also laid out plans for the company to diversify, aiming to emerge from the loss of exclusivity period as a larger and more diversified entity. The company intends to have at least five Phase 3 programs in obesity and diabetes, and at least five in other therapeutic areas. Despite these strategic outlines, the market reacted negatively, with shares ultimately down around 5% by day's end, reflecting skepticism about the pace and impact of these long-term initiatives on immediate competitive pressures.
